Abstract Reduced cerebral blood flow (CBF) and cerebrovascular function are critical early-stage biomarkers preceding changes in brain function and structure observed in normal aging and during the onset and progression of Alzheimers Disease and related dementias (ADRD)
Its utility as a backbone therapy, with a broad range of risk reduction and treatment benefits may erode the market potential of newer, indication-specific therapies, even in areas where semaglutide is not yet explicitly approved, but initial trial readouts show promising results, e.g
Funding Financial support by the Core Research Grant, SERB, Department of Science and Technology, India (Grant No
Researchers interested in peptide handling, storage recommendations, HPLC analysis, LC-MS verification, and laboratory best practices are encouraged to visit our Research Peptide Guides
doi:10.1016/j.tips.2009.07.002